{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:13:37Z","timestamp":1790993617489,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta\u2010analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta\u2010analysis of the literature published from inception to Dec 31, 2016 was conducted. Case\u2010control studies with vitiligo patients and a control group were included. The prevalence of anti\u2010thyroperoxidase (ATPO) antibodies, anti\u2010thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti\u2010gastric parietal cell antibodies (AGPCA), anti\u2010smooth muscle antibodies (ASMA), anti\u2010mitochondrial antibodies (AMA), and anti\u2010adrenal antibodies in vitiligo patients were 15.1\u00a0%, 9.7\u00a0%, 12.5\u00a0%, 11.7\u00a0%, 12.6\u00a0%, 0.2\u00a0%, and 2.5\u00a0%, respectively. The prevalence of ATPO antibodies (odds ratio [OR]: 3.975; 95\u00a0%; confidence interval [CI]: 3.085\u20135.122), ATG antibodies (OR: 3.759; 95\u00a0% CI: 2.554\u20135.531), ANA (OR: 1.797, 95\u00a0% CI: 1.182\u20132.731), AGPCA (OR: 2.503; 95\u00a0% CI: 1.497\u20132.896), and anti\u2010adrenal antibodies (OR: 9.808, 95\u00a0% CI: 1.809\u201353.159) (Figure 2a\u2013e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti\u2010thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.<\/jats:p>","DOI":"10.1111\/ddg.13574","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T15:57:04Z","timestamp":1530719824000},"page":"845-851","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vitiligo and autoantibodies: a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"16","author":[{"given":"Che\u2010Wei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Orthopedics Cathay General Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Chen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wan Fang Hospital Taipei Medical University  Taipei Taiwan"},{"name":"Department of Dermatology School of Medicine College of Medicine Taipei Medical University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(69)91421-4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02089.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11198.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1983.01650280028010"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.19200"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1993.tb01363.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1996.tb01609.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000249466"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2012.01712.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.135485"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91889-7"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2008.060509"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.2007.00408.x"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:20:05Z","timestamp":1695010805000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/ddg.13574"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13574","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"2017-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}